The Role of the Level of Interleukin-33 in the Therapeutic Outcomes of Immunotherapy in Patients with Allergic Rhinitis
19 October 2016
03 July 2017
28 August 2017 (eFirst)
Introduction Allergic rhinitis (AR) affects up to 40% of the population and results in nasal itching, congestion, sneezing, and clear rhinorrhea.
Objectives This study aimed to evaluate the changes in the clinical symptoms and in the level of serum interleukin (IL)-33 before and after pollen immunotherapy (IT) in patients with AR.
Methods The total symptom score and the levels of total immunoglobulin E (IgE) and IL-33 were determined in the serum of 10 non-allergic healthy controls and 45 patients with AR who were equally divided into 3 groups: GI (patients did not receive IT), GII (patients had received IT for 6 months) and GIII (patients had received IT for 2 years).
Results There was a significantly higher concentration of IgE and IL-33 in the serum of patients with AR than in that of non-allergic patients. Furthermore, serum level of IL-33 decreased significantly after pollen IT. But, there was no significant reduction in the serum level of IL-33 between GII and GIII patients.
Conclusion Our results show a clinical improvement associated with a decrease in serum level of IL-33 after pollen IT.
- 1 Uzzaman A, Story R. Chapter 5: Allergic rhinitis. Allergy Asthma Proc 2012; 33 (Suppl. 01) S15-S18
- 2 Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. Immunol Allergy Clin North Am 2011; 31 (03) 561-599
- 3 Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol 2012; 158 (Suppl. 01) 47-50
- 4 Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res 2012; 61 (06) 547-550
- 5 Schatz M, Meltzer EO, Nathan R. , et al. Psychometric validation of the rhinitis control assessment test: a brief patient-completed instrument for evaluating rhinitis symptom control. Ann Allergy Asthma Immunol 2010; 104 (02) 118-124
- 6 Passalacqua G, Durham SR. ; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119 (04) 881-891
- 7 Bousquet J, Khaltaev N, Cruz AA. , et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86) 8-160
- 8 Shaaban R, Zureik M, Soussan D. , et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372 (9643): 1049-1057
- 9 Walker SM, Durham SR, Till SJ. , et al; British Society for Allergy and Clinical Immunology. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011; 41 (09) 1177-1200
- 10 Durham SR, Emminger W, Kapp A. , et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129 (03) 717-725.e5
- 11 Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010; 40 (02) 200-208
- 12 Boghdadi G, Marei A, Ali A, Lotfy G, Abdulfattah M, Sorour S. Immunological markers in allergic rhinitis patients treated with date palm immunotherapy. Inflamm Res 2012; 61 (07) 719-724
- 13 Kamekura S. Expression of IL-33 in the nasal epithelium of patients with AR and production of cytokines/ chemokines. Clin Exp Allergy 2012; 80: 531-538
- 14 Haenuki Y, Matsushita K, Futatsugi-Yumikura S. , et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 2012; 130 (01) 184-94.e11
- 15 Du Y, Luo Y, Yang C, Liu J, Wan J, Wang K. [Discussion IL-33 and its receptor ST2 associated with the pathogenesis of allergic rhinitis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2015; 29 (09) 811-814
- 16 Yoshimoto T, Matsushita K. Innate-type and acquired-type allergy regulated by IL-33. Allergol Int 2014; 63 (Suppl. 01) 3-11
- 17 Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354 (01) 24-31
- 18 Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013; 131 (05) 1361-1366